Resistance profiles to antiretroviral drugs in HIV-1 drug-naive patients in Argentina

Antiviral Therapy

Volumn 6, Issue 1, 2001, Pages 71-77

  Kijak, Gustavo H ^a   Pampuro, Sandra E ^a   Avila, María M ^a   Zala, Carlos ^b   Cahn, Pedro ^b   Wainberg, Mark A ^c   Salomón, Horacio ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Huesped Foundation   (Argentina)

^c MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PROTEINASE; RNA DIRECTED DNA POLYMERASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANTIBIOTIC RESISTANCE; ARGENTINA; ARTICLE; DRUG EFFECT; FEMALE; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; MALE; MUTATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; ARGENTINA; DRUG RESISTANCE, MICROBIAL; FEMALE; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MUTATION;

EID: 0035288397     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Ho DD, Neumann AU, Perelson AS, Chen W Leonard JM & Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995; 373:123-126.
2. Mansky LM & Temin HM. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. Journal of Virology 1995; 69:5087-5094
3. Wainberg MA & Friedland G. Public health implications of antiretroviral therapy and HIV drug resistance. Journal of the American Medical Association 1998; 279:1977-1983
4. Schinazi R, Larder B & Mellors J. Mutations in retroviral genes associated in drug resistance. International Antiviral News 1997; 5:129-142
5. Erice A, Mayers DL, Strike DG, Sannerud KJ, McCutchan FE, Henry K & Balfour HH Jr. Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. New England Journal of Medicine 1993; 328:1163-1165.
6. Najera I, Richman DD, Olivares I, Rojas JM, Peinado MA, Perucho M, Najera R & Lopez-Galindez C. Natural occurrence of drug resistance mutations in the reverse transcriptase of human immunodeficiency virus type 1 isolates. AIDS Research and Human Retroviruses 1994; 10:1479-1488
7. Ribeiro RM & Bonhoeffer S. Production of resistant HIV mutants during antiretroviral therapy. Proceedings of the National Academy of Sciences, USA 2000; 97:7681-7686.
8. Little SJ. Transmission and prevalence of HIV resistance among treatment-naive subjects Antiviral Therapy 2000; 5:33-40.
9. Salomon H, Wainberg MA, Brenner B, Quan Y, Rouleau D, Coté P, LeBlanc R, Lefebvre E, Spira B, Tsoukas C, Sekaly RP, Conway B, Mayers D, Routy JP & Investigators of the Quebec Primary Infection Study. Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. AIDS 2000; 14:F17-F23.
10. Little SJ, Daar DS, D'Aquila RT, Keiser PH, Connick E, Whitcomb JM, Hellmann NS, Petropoulos CJ, Sutton L, Pitt JA, Rosenberg ES, Koup RA, Walker BD & Richman DD. Reduced antiretroviral drugs suceptibility among patients with primary HIV infection. Journal of the American Medical Association 1999; 282:1142-1149.
11. Boden D, Hurley A, Zhang LQ, Cao YZ, Guo Y, Jones E, Tsay J, Ip J, Farthing C, Limoli K, Parkin N & Markowitz M. HIV-1 drug resistance in newly infected individuals. Journal of the American Medical Association 1999; 282:1135-1141.
12. th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January - 2 February 2000. Abstr. 748.
13. Hirsch MS, Brun-Vézinet F, D'Aquila RT, Hammer SM, Johnson VA, Kuritzkes DR, Loveday C, Mellors JW, Clotet B, Conway B, Demeter LM, Vella S, Jacobsen DM & Richman DM. Antiretroviral drug resistance testing in adult HFV-1 infection. Journal of the American Medical Association 2000; 283:2417-2426.
14. Ministry of Health, Buenos Aires, Argentina. Boletín sobre el SIDA en la Argentina 1999; 18:6-7.
15. Salomón H, Belmonte A, Nguyen K, Gu Z, Gelfand M & Wainberg MA. Comparison of cord blood and peripheral blood mononuclear cells as targets for viral isolation and drug sensitivity studies involving human immunodeficiency virus type 1. Journal of Clinical Microbiology 1994; 32:2000-2002
16. Villahermosa ML, Contreras G, Perez-Alvarez L, Bru F, Medrano L, Delgado E, Colomo C, Thomson M & Najera R. Evaluation or mixtures of wild-type HIV-1 and HIV-1 with resistance point mutations against reverse transcriptase inhibitors. Antiviral Therapy 1998; 3:221-227
17. Stuyver L, Wyseur A, Rombout A, Louwagie J, Scarcez T, Verhofstede C, Rimland D, Schinazi RF & Rossau R. Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrobial Agents & Chemotherapy 1997; 41:284-291.
18. Thompson JD, Higgins DG & Gibson TJ. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Research 1994; 22:4673-4680.
19. Hammond J, Calef C, Larder B, Schinazi R & Mellors JW. Mutations in retroviral genes associated with drug resistance in human retroviruses and AIDS 1998: a compilation and analysis of nucleic acid and amino acid sequences. Edited by B Korber, B Hahn, B Foley, F McCutchan, C Kuiken, B Hahn, JW Mellors & J Soroski. 1998; pp. III-36- III-79. Los Alamos, N.M., USA: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory.
20. Larder BA & Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989; 246:1155-1158.
21. Patick AK, Duran M, Cao Y, Shugarts D, Keller MR, Mazabel E, Knowles M, Chapman S, Kuritzkes DR & Markowitz M. Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrobial Agents & Chemotherapy 1998; 42:2637-2644.
22. Martinez-Picado J, Savara AV, Sutton L & D'Aquila. RT. Replicative fitness of protease inhibitor-resistant mutants of human immunodeficiency virus type 1. Journal of Virology 1999; 73:3744-3752.
23. Condra JH, Holder DJ, Schleif WA, Blahy OM, Danovich RM, Gabryelski LJ, Graham DJ, Laird D, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Yang T, Chodakewitz JA, Deutsch PJ, Leavitt RY, Massari FE, Mellors JW, Squires KE, Steigbigel RT, Teppler H & Emini EA. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. Journal of Virology 1996; 70:8270-8276.
24. Schinazi RF, Lloyd RM Jr, Nguyen MH, Cannon DL, McMillan A, Ilksoy N, Chu CK, Liotta DC, Bazmi HZ & Mellors JW. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrobial Agents & Chemotherapy 1993; 37:875-881.
25. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, Montagne N, Boucher CA, Schapiro JM & Dellamonica P. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 1999; 353:2195-21999.
26. Grant R, Hescht E, Petropoulos C, Hellman N, Warmerdam M, Brandapalli N, Gittens T, Chesney M & Kahn J. Trends in prevalence of primary HIV-1 drug resistance among recently infected persons in San Francisco. Antiviral Therapy 1999; 4(Suppl. 1):98.
27. Miller V, Perrin N, Modai J, Clumeck N, Johnson M, Gazzard B, Montaner J, Gaines H, Bloch N, Larder B, Beau vais L, Goh L, Girard P & Sonnerborg A. Prevalence of baseline drug resistance mutations in primary HIV infection patients from the QUEST Study. Antiviral Therapy 1999; 4(Suppl. 1):60.
28. th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif., USA. Abstr. I-58.
29. Verbiest W, Schel P, Conant M, Van Den Broeck R, Blor S, Alcorn T, Stoffels P, Larder B & Hertogs K. An epidemiological prospective survey assessing the prevalence of HIV-1 resistance in 230 HIV-1-possitive antiretroviral-naive patients of the USA. Antiviral Therapy 1999; 4(Suppl. 1):86.
30. Wegner S, Brodine S, Mascola J, Barile A, Aronson N, Martin G, Stephan K, Tasker S, Emmons W, Shaffer R, Blor S, Vingerhoets J, Hertogs K & Larder B. High frequency of antiretroviral drug resistance in HIV-1 from recently infected therapy-naive individuals. Antiviral Therapy 1999; 4(Suppl 1):85.
31. Descamps D, Costaghola D, Glaude G, Buffet-Janvresse C, Calvez V, Collin G, Cottalorda J, Ferchal F, Harzic M, Izopet J, Maquelier B, Fufffault A, Schmuck A, Tamalet C, Yvon A & Brun-Vézinet F. Prevalence of resistance mutations in antiretroviral-naïve patients: French National Study. Antiviral Therapy 1999; 4(Suppl. 1):87.
32. Gomez-Cano M, Rubio A, Puig T, Perez-Olmeda M, Ruiz L, Soriano V, Pineda JA, Zamora L, Xaus N, Clotet E & Leal M. Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naïve and antiretroviral-experienced HIV-infected patients in Spain. AIDS 1998; 12:1015-1020.
33. Kemp SD, Shi C, Bloor S, Harrigan PR, Mellors JW & Larder BA. A novel polymorphism at codon 333 of human immunodeficiency virus yype 1 reverse transcriptase can facilitate dual resistance to zidovudine and 1-2′,3′-dideoxy-3′-thiacytidine. Journal of Virology 1998; 72:5093-5098.
34. Vergne L, Peeters M, Mpoudi-Ngole E, Bourgeois A, Liegeois F, Tourke-Kane C, Mboup S, Mulanga-Kabeya C, saman E, Jourdan J, Reynes J & Delaporte E. Genetic Diversity of protease and reverse transcriptase sequences in non-B human immunodeficiency virus type 1 strains: evidence of many minor drug resistance mutations in treatment-naive patients. Journal of Clinical Microbiology 2000; 38:3919-3925.
35. Gunthard HF, Wong JK, Ignacio CC, Havlir DV & Richman DD. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Research and Human Retroviruses 1998; 14:869-876.
36. Schuurman R, Demeter L, Reichelderfer P, Tijnagel J, de Groot T & Boucher C. Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. Journal of Clinical Microbiology 1999; 37:2291-2296.
37. Kaye S, Comber E, Tenant-Flowers M & Loveday C. The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA. AIDS Research and Human Retroviruses 1995; 11:1221-1225.